Ovarian Cancer: Risk Factors, Symptoms, and Early Detection

Ovarian cancer ranks as the fifth leading cause of cancer death among women in the United States, according to the National Cancer Institute (NCI), with approximately 19,680 new diagnoses and 12,740 deaths projected for 2024. Because the ovaries sit deep within the pelvic cavity, tumors frequently grow without producing obvious symptoms until they have spread beyond the pelvis — a staging pattern that sharply reduces survival outcomes. This page covers the major histological types, established risk factors, recognized symptom clusters, and the evidence base for current detection approaches.

Definition and Scope

Ovarian cancer is not a single disease but a group of malignancies arising from different cell types within or adjacent to the ovary. The National Cancer Institute classifies ovarian malignancies into three primary categories based on the tissue of origin:

  1. Epithelial ovarian carcinoma — Originates in the outer surface layer (epithelium) of the ovary and accounts for approximately 90% of all ovarian cancers. High-grade serous carcinoma (HGSC) is the most common and aggressive subtype within this group.
  2. Germ cell tumors — Arise from the egg-producing cells; these represent roughly 2–3% of cases and occur predominantly in women under age 30.
  3. Sex cord-stromal tumors — Develop from the connective tissue cells that produce hormones; they account for approximately 1–2% of cases and include granulosa cell tumors and Sertoli-Leydig cell tumors.

The distinction between types carries direct clinical consequence. Germ cell tumors, for example, respond well to platinum-based chemotherapy and carry a five-year survival rate exceeding 90% for localized disease (NCI SEER Database), while high-grade serous carcinoma diagnosed at Stage III or IV carries a five-year relative survival rate of approximately 29%.

The Food and Drug Administration (FDA) regulates diagnostic devices and companion diagnostics used in ovarian cancer workup, including BRCA mutation tests and the CA-125 blood assay. The regulatory landscape governing these tools is detailed in the broader regulatory context for women's health.

How It Works

Biological Mechanism

High-grade serous carcinoma, the dominant subtype, is now understood to originate in most cases not from the ovarian surface epithelium itself but from the fimbriated end of the fallopian tube (Society of Gynecologic Oncology, SGO). Precancerous lesions called serous tubal intraepithelial carcinomas (STICs) shed malignant cells that implant on the ovarian surface and peritoneum, explaining why the disease often presents as widespread peritoneal carcinomatosis even at initial diagnosis.

Hereditary Risk Pathways

Approximately 15–20% of high-grade serous ovarian carcinomas are linked to inherited mutations in BRCA1 or BRCA2 (NCI, BRCA Gene Mutations). The lifetime risk of developing ovarian cancer is estimated at 44% for BRCA1 mutation carriers and 17% for BRCA2 mutation carriers, compared with approximately 1.2% in the general population. Lynch syndrome — caused by mutations in mismatch repair genes including MLH1, MSH2, MSH6, and PMS2 — confers a lifetime ovarian cancer risk of 4–24% depending on the specific gene involved (National Comprehensive Cancer Network, NCCN).

For a broader discussion of inherited cancer susceptibility across gynecologic malignancies, see the resource on hereditary cancer risk in women.

Established Risk Factors

Beyond germline mutations, the following factors are associated with increased ovarian cancer risk based on epidemiological evidence compiled by the American Cancer Society (ACS):

Factors associated with reduced risk include oral contraceptive use (approximately 50% risk reduction after 5 or more years of use, per ACS), breastfeeding, and bilateral tubal ligation.

Common Scenarios

Symptom Presentation

Ovarian cancer produces symptoms that are nonspecific and frequently attributed to gastrointestinal or musculoskeletal causes. The Ovarian Cancer Research Alliance (OCRA) and the CDC identify four symptom clusters that, when persistent (occurring more than 12 times per month for less than one year), warrant prompt evaluation:

  1. Bloating
  2. Pelvic or abdominal pain
  3. Difficulty eating or feeling full quickly
  4. Urinary urgency or frequency

Because these symptoms overlap substantially with irritable bowel syndrome, urinary tract conditions, and other benign conditions, diagnosis is frequently delayed. The median time from symptom onset to diagnosis has been documented at 3–6 months in multiple clinical series cited by the Society of Gynecologic Oncology.

Ovarian Cysts vs. Ovarian Cancer

A critical clinical distinction exists between benign ovarian cysts and malignant ovarian neoplasms. Most simple cysts — fluid-filled structures with smooth walls and no internal architecture — are benign and require only surveillance. Malignant or borderline lesions typically show complex morphology on imaging: solid components, internal septations, papillary projections, and increased vascularity on Doppler ultrasound.

Decision Boundaries

Screening: What the Evidence Supports

No validated population-level screening test for ovarian cancer currently exists for average-risk women. The U.S. Preventive Services Task Force (USPSTF) issued a Grade D recommendation against ovarian cancer screening in asymptomatic average-risk women, based on evidence that screening with CA-125 and transvaginal ultrasound (TVU) does not reduce mortality and leads to harms from false-positive results, including unnecessary surgical procedures.

The landmark PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial, a randomized controlled trial involving more than 78,000 women, found that annual CA-125 and TVU screening did not reduce ovarian cancer mortality (NCI, PLCO Trial).

High-Risk Surveillance Protocols

Women with confirmed BRCA1 or BRCA2 mutations or Lynch syndrome are managed under different protocols. The NCCN recommends that BRCA1 carriers consider risk-reducing salpingo-oophorectomy (RRSO) between ages 35 and 40, and BRCA2 carriers between ages 40 and 45. Interim surveillance with CA-125 and TVU every 6 months may be offered, though the NCCN explicitly notes this has not been proven to reduce mortality.

Diagnostic Workup Sequence

When ovarian cancer is clinically suspected, the standard diagnostic pathway follows this sequence:

  1. Pelvic examination — Initial physical assessment for adnexal masses.
  2. Transvaginal ultrasound (TVU) — First-line imaging for characterizing ovarian morphology.
  3. Serum CA-125 — Elevated in approximately 80% of epithelial ovarian cancers at advanced stage, but only 50% of Stage I cases; useful in combination with imaging.
  4. CT scan of abdomen and pelvis — Used to evaluate extent of disease and surgical planning, not for primary diagnosis.
  5. Surgical staging — Definitive diagnosis requires histopathological examination of tissue; imaging findings alone are insufficient for staging under FIGO (International Federation of Gynecology and Obstetrics) criteria.

The FDA-cleared Risk of Ovarian Malignancy Algorithm (ROMA), which combines CA-125 and HE4 biomarker levels with menopausal status, is validated to stratify patients into high- and low-risk categories for surgical referral — not as a standalone diagnostic test.

Decisions about surgical timing, chemotherapy sequencing, and PARP inhibitor eligibility are governed by guidelines from the NCCN and are outside the scope of informational review. The Women's Health Authority index provides an orientation to the full range of gynecologic and oncologic

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)